OTLK - Outlook Pharma Analyst Forecast Prices

Outlook Therapeutics (OTLK) is a biopharmaceutical player adapting bevacizumab for the treatment of wet AMD and implementing ESG principles by greening laboratories with safe waste disposal. This daily price action for the company's shares visualized on the GURU.Markets platform is currently at 6.19. Moving forward, the pricing of new retinal dystrophy treatments will be constrained by the market presence of affordable non-licensed substitutes.

Outlook Therapeutics - OTLK Price Target Chart (period 07/04/2022 - 11/11/2026)

Analytical breakdowns for Outlook Pharma (OTLK)

- current quotes and average value forecast:

Market Price outlooktherapeutics.com|OTLK - Consensus Target

- market capitalization statistics:

Market Value Outlook Pharma|OTLK - Total Company Value

- book capitalization information:

Net Assets per Single Share Outlook Therapeutics|OTLK - Company Book Value|Market Capitalization to Book Value Ratio outlooktherapeutics.com|OTLK - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

Aggregate Debt to Equity Outlook Therapeutics|OTLK - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Outlook Therapeutics Corp|OTLK - Company Aggregate Debts|Debts to Book Capitalization Outlook Pharma|OTLK - Company Long-Term Debt|Company Short-Term Loans and Borrowings Outlook Therapeutics|Quick Liquidity Indicator outlooktherapeutics.com

- financial results and valuation multiples details:

OTLK - Net Profit|Projected Future Earnings Outlook Therapeutics|OTLK - Price to Earnings Ratio|Future Price to Earnings Multiple Outlook Therapeutics Inc|OTLK - PEG Multiple|Company Value to EBITDA Outlook Pharma|OTLK - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Outlook Therapeutics|OTLK - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months outlooktherapeutics.com|OTLK - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Outlook Therapeutics

General company analysis:OTLK outlooktherapeutics.com

Flagship merchandise of Outlook Therapeutics Corp

This indicator represents the aggregated average of target prices from leading investment houses, reflecting the market consensus regarding the asset's fair value. For Outlook Therapeutics (OTLK), which lacks stable revenue due to its clinical trial stage, the average target price level serves as a marker for regulatory approval expectations, where any break in the trend line signals a reassessment of the business's fundamental prospects.

Competitors of Outlook Therapeutics